Good morning, all. Damian Garde here, filling in for Ed Silverman on what is another relatively quite morning in pharma’s inter-holiday interregnum. Read on for some tidbits from around the industry and enjoy the little respite before everyone gets back to their desks next week.
Biogen’s new drug, for the rare disease spinal muscular atrophy, is going to cost $375,000 per year, The Boston Globe reports. Here’s how that breaks down: Each dose of the treatment, called Spinraza, costs $125,000. Patients starting therapy need six doses in the first year, amounting to an initial cost of $750,000, followed by three doses each ensuing year, making for a $375,000 annual price from then on.